Stoke Therapeutics, Inc.STOKNASDAQ
Loading
SG&A Expense Growth AcceleratingAccelerating
Percentile Rank87
5Y CAGR+86.7%
Year-over-Year Change
Year-over-year SG&A expense growth
5Y CAGR
+86.7%/yr
Long-term compound
Percentile
P87
Within normal range
vs 5Y Ago
22.7x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 32.40% |
| Q3 2025 | 1.43% |
| Q2 2025 | 4.16% |
| Q1 2025 | 14.08% |
| Q4 2024 | 1.20% |
| Q3 2024 | 1.74% |
| Q2 2024 | 29.01% |
| Q1 2024 | -3.48% |
| Q4 2023 | 3.20% |
| Q3 2023 | 0.35% |
| Q2 2023 | 0.13% |
| Q1 2023 | 9.29% |
| Q4 2022 | -6.04% |
| Q3 2022 | -1.77% |
| Q2 2022 | 5.15% |
| Q1 2022 | 4.41% |
| Q4 2021 | 4.79% |
| Q3 2021 | 4.93% |
| Q2 2021 | 14.75% |
| Q1 2021 | 21.68% |
| Q4 2020 | 1.43% |
| Q3 2020 | 11.06% |
| Q2 2020 | 11.59% |
| Q1 2020 | 13.60% |
| Q4 2019 | 19.71% |
| Q3 2019 | 37.24% |
| Q2 2019 | 10.64% |
| Q1 2019 | 42.33% |
| Q4 2018 | 41.10% |
| Q3 2018 | -2.85% |
| Q2 2018 | 70.00% |
| Q1 2018 | 0.00% |